• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ABCIXIMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • ABCIXIMAB chembl:CHEMBL1201584 Approved

    Alternate Names:

    ABCIXIMAB
    ABCIXIMAB (GENETICAL RECOMBINATION)
    C7E3
    REOPRO
    7E3
    7E3 ANTIBODY
    ANTIGPIIBIIIA
    ABCIXIMAC
    drugbank:00054
    chembl:CHEMBL1201584
    rxcui:83929
    chemidplus:143653-53-6
    pubchem.compound:3815015

    Drug Info:

    Year of Approval 1997
    Drug Class anticoagulants
    Drug Class antiplatelet agents
    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications anticoagulant
    (2 More Sources)

    Publications:

    Mazzaferri et al., 2008, Abciximab: a review and update for clinicians., Expert Rev Cardiovasc Ther
    Gibbs, 2009, Point-of-care assessment of antiplatelet agents in the perioperative period: a review., Anaesth Intensive Care
    Ibbotson et al., 2003, Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation., Drugs
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics
    Hall et al., 2007, Characterization and NMR solution structure of a novel cyclic pentapeptide inhibitor of pathogenic hantaviruses., Chem Biol Drug Des
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Weber et al., 2002, Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors., Thromb. Res.
    Amoroso et al., 2001, Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease., J. Cardiovasc. Pharmacol.
  • ABCIXIMAB   ITGA2B

    Interaction Score: 9.16

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor
    Direct Interaction yes
    Trial Name abciximab, c7E3,ReoPro

    PMIDs:
    18510478 19499855 12749745 20938371


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • ABCIXIMAB   ITGB3

    Interaction Score: 8.1

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Integrin alpha-IIb/beta-3 inhibitor
    Direct Interaction yes
    Trial Name abciximab, c7E3,ReoPro

    PMIDs:
    20938371 17441904 12749745 11752352 18510478 12165285 11588534


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • ABCIXIMAB   FGG

    Interaction Score: 4.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • ABCIXIMAB   FGB

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • ABCIXIMAB   FGA

    Interaction Score: 2.58

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20938371


    Sources:
    PharmGKB

  • ABCIXIMAB   ITGAV

    Interaction Score: 1.03

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Integrin alpha-V/beta-3 inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • TEND: ABCIXIMAB

    • Version: 01-August-2011

    Alternate Names:
    ABCIXIMAB Primary Drug Name

    Drug Info:
    Drug Class antiplatelet agents
    Drug Class anticoagulants
    Year of Approval 1997

    Publications:

  • TdgClinicalTrial: ABCIXIMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications anticoagulant
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • PharmGKB: abciximab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Sangkuhl K et al., 2011, Platelet aggregation pathway., Pharmacogenet Genomics

  • TTD: Abciximab

    • Version: 2020.06.01

    Alternate Names:
    D0P3TX TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201584

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201584

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21